Precigen Inc.’s stock surged 144% in August 2025 after the FDA approved its pioneering therapy for a rare lung disease, boosting investor confidence and positioning the biopharmaceutical company for further growth.

The Tumor-Infiltrating Lymphocyte (TIL) Therapy Market is gaining momentum, driven by expanding oncology applications and advancements in cell-based immunotherapy.

Precigen Inc. is a biopharmaceutical company pioneering gene and cell therapies to tackle complex health issues, revolutionizing the healthcare industry with innovative solutions.

Precigen, Inc. is a biopharmaceutical company pioneering the development of groundbreaking gene and cell therapies to address various health issues, including immuno-oncology, autoimmune disorders, and infections.